Expression levels of gastrointestinal hormones in the progression of liver fibrosis in patients with nonalcoholic fatty liver disease

Humin ZHU; Xudong LIU; Lu HUANG; Pinhua LI; Tiexiong WU; Huazhen PANG

doi:10.3969/j.issn.1001-5256.2021.10.021

Volume 37 Issue 10

Oct. 2021

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2021 > 37(10): 2364-2368

PDF( 1909 KB)

Expression levels of gastrointestinal hormones in the progression of liver fibrosis in patients with nonalcoholic fatty liver disease

DOI: 10.3969/j.issn.1001-5256.2021.10.021

1.
Graduate School, Guangxi University of Chinese Medicine, Nanning 530000, China
2.
Department of Hepatology, Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, Nanning 530000, China

Research funding:

Guangxi Key Science and Technology Program (GK AB18221009);

Guangxi First-class Discipline Construction Project (2019XK139);

Project of High-level Talent Team Cultivation in Qihuang Program of Guangxi University of Chinese Medicine (2021007)

Received Date: 2021-03-02
Accepted Date: 2021-03-23
Published Date: 2021-10-20

Abstract

Abstract

Objective To investigate the changes in gastrointestinal hormones during the progression of liver fibrosis in patients with nonalcoholic fatty liver disease (NAFLD), and to provide a basis for digestive function impairment. Methods A prospective analysis was performed for 326 patients with NAFLD who attended the outpatient service and were hospitalized and treated in Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine from October 2018 to June 2020, and FibroTouch was used to measure liver stiffness measurement (LSM). According to the presence or absence of liver fibrosis, they were divided into non-liver fibrosis group (group A, 161 patients with LSM < 7.3 kPa) and liver fibrosis group (group B, 165 patients with LSM ≥7.3 kPa). According to the fibrosis degree, the patients were further divided into F0-1 group (LSM < 7.3 kPa), F2 group (7.3 kPa ≤LSM < 9.7 kPa), F2-3 group (9.7 kPa ≤LSM < 12.4 kPa), F3-4 group (12.4 kPa ≤LSM < 17.5 kPa), and F4 group (LSM ≥17.5 kPa). Related data were collected, including age, sex, liver function parameters, and gastrointestinal hormones. The independent samples t-test and the one-way analysis of variance were used for comparison of normally distributed continuous data between groups, and the nonparametric Mann-Whitney U test and the Kruskal-Wallis H test were used for comparison of non-normally distributed continuous data between groups. A Spearman correlation analysis was used to investigate the correlation between LSM and liver function parameters. Results Comparison of liver function and gastrointestinal hormones showed that there were significant differences between groups A and B in alanine aminotransferase (ALT) (Z=-3.778, P < 0.001), aspartate aminotransferase (AST) (Z=-3.320, P=0.001), gamma-glutamyl transpeptidase (GGT) (Z=-3.040, P=0.002), cholecystokinin (CCK) (t=-2.944, P=0.003), and lipopolysaccharide (LPS) (Z=-2.317, P=0.020). There were significant differences in ALT (χ²=23.113, P < 0.001), AST (χ²=23.415, P < 0.001), ALP (χ²=15.962, P=0.003), GGT (χ²=20.172, P < 0.001), and CCK (F=2.687, P=0.031) between the F0-1 group with 161 patients, the F2 group with 89 patients, the F2-3 group with 46 patients, the F3-4 group with 16 patients, and the F4 group with 14 patients. LSM was positively correlated with direct bilirubin, ALT, AST, alkaline phosphatase, and GGT (r=0.128, 0.266, 0.225, 0.137, and 0.213, all P < 0.05). Conclusion Liver fibrosis progression in NAFLD can affect gallbladder contraction function and gastrointestinal function, and measurement of the serum levels of CCK and LPS has an important clinical value in the early diagnosis and treatment of digestive diseases related to gallbladder contraction function and gastrointe stinal function in NAFLD patients with liver fibrosis.
- Non-Alcoholic Fatty Liver Disease,
- Liver Cirrhosis,
- Gastrointestinal Hormones

FullText(HTML)

References(28)

References

[1]	HUBER Y, GALLE PR, SCHATTENBERG JM. What is the (right) target for non-alcoholic fatty liver disease (NAFLD)?[J]. Z Gastroenterol, 2020, 58(1): 68-73. DOI: 10.1055/a-1068-3981.
[2]	STINE JG, WENTWORTH BJ, ZIMMET A, et al. Systematic review with meta-analysis: Risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases[J]. Aliment Pharmacol Ther, 2018, 48(7): 696-703. DOI: 10.1111/apt.14937.
[3]	MACALUSO FS, MAIDA M, PETTA S. Genetic background in nonalcoholic fatty liver disease: A comprehensive review[J]. World J Gastroenterol, 2015, 21(39): 11088-11111. DOI: 10.3748/wjg.v21.i39.11088.
[4]	Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Gastroenterology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Consensus on the diagnosis and therapy of hepatic fibrosis(2019)[J]. J Clin Hepatol, 2019, 35(10): 2163- 2172. DOI: 10.3969/j.issn.1001-5256.2019.10.007. 中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会感染病学分会. 肝纤维化诊断及治疗共识(2019年)[J]. 临床肝胆病杂志, 2019, 35(10): 2163-2172. DOI: 10.3969/j.issn.1001-5256.2019.10.007.
[5]	National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association, Fatty Liver Expert Committee, Chinese Medical Doctor Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease: A 2018 update[J]. J Clin Hepatol, 2018, 34(5): 947-957. DOI: 10.3969/j.issn.1001-5256.2018.05.007. 中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018年更新版)[J]. 临床肝胆病杂志, 2018, 34(5): 947-957. DOI: 10.3969/j.issn.1001-5256.2018.05.007.
[6]	HAGSTRÖM H, NASR P, EKSTEDT M, et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD[J]. J Hepatol, 2017, 67(6): 1265-1273. DOI: 10.1016/j.jhep.2017.07.027.
[7]	ARCHER S, DAVIES K. Biological basis of child health 9: Development of the liver and clinical features of childhood liver disease[J]. Nurs Child Young People, 2021. DOI: 10.7748/ncyp.2021.e1258.[Online ahead of print]
[8]	WANG SK, CHEN DH. The serum levels and their clinical significance of retinol-binding protein and several liver function index in different types of liver disease[J]. Chin J Health Lab Technol, 2017, 27(8): 1065-1067. https://www.cnki.com.cn/Article/CJFDTOTAL-ZWJZ201708001.htm 王胜奎, 陈戴红. 常见肝脏疾病患者血清视黄醇结合蛋白表达水平及部分肝功能指标联合检测的临床意义[J]. 中国卫生检验杂志, 2017, 27(8): 1065-1067. https://www.cnki.com.cn/Article/CJFDTOTAL-ZWJZ201708001.htm
[9]	HAN L, WEN QS. Relationship between serum uric acid and non-alcoholic fatty liver disease in male adults[J]. Chin J Integr Trad West Med Dig, 2015, 23(7): 496-500. DOI: 10.3969/j.issn.1671-038X.2015.07.13. 韩琳, 温巧生. 血清尿酸与男性非酒精性脂肪肝的相关性研究[J]. 中国中西医结合消化杂志, 2015, 23(7): 496-500. DOI: 10.3969/j.issn.1671-038X.2015.07.13.
[10]	LIU WY, GAO XZ. Analysis of the value of serum pepsinogen, gastrin-17, and Helicobacter pylori antibody detection in screening gastric cancer risk groups[J/CD]. Chin J Gastrointest Endosc(Electronic Edition), 2021, 8(1): 37-41. DOI: 10.3877/cma.j.issn.2095-7157.2021.01.007. 刘炜钰, 高孝忠. 血清胃蛋白酶原、胃泌素-17、幽门螺杆菌抗体检测在筛查胃癌风险人群中的价值分析[J/CD]. 中华胃肠内镜电子杂志, 2021, 8(1): 37-41. DOI: 10.3877/cma.j.issn.2095-7157.2021.01.007.
[11]	CHAI CH, LI LQ, CHEN P, et al. Detection and clinical analysis of fasting serum gastrin in patients with various liver diseases[J]. J Zunyi Med Coll, 1995, 18(3): 190-192. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYYB199503013.htm 柴朝会, 李良庆, 陈萍, 等. 各型肝病患者空腹血清胃泌素检测与临床分析[J]. 遵义医学院学报, 1995, 18(3): 190-192. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYYB199503013.htm
[12]	WILLIAMS RL. Textbook of endocrinology[M]. 6th ed. Philadelphia: Saunders, 1981: 704-705.
[13]	SVENBERG T, NILSSON I, SAMUELSON K, et al. Studies on the causal relationship between gall-bladder emptying and motilin release in man[J]. Acta Chir Scand Suppl, 1984, 520: 59-61.
[14]	QIN J, ZHOU SZ, ZHANG YJ. Analysis of related factors of liver cirrhosis on gastrointestinal motility[J]. Hubei J Prevent Med, 2001, 12: 47-48. https://www.cnki.com.cn/Article/CJFDTOTAL-FBYF2001S1043.htm 秦俊, 周韶璋, 张一洁. 肝硬化对胃肠动力学影响的相关因素分析[J]. 湖北预防医学杂志, 2001, 12: 47-48. https://www.cnki.com.cn/Article/CJFDTOTAL-FBYF2001S1043.htm
[15]	CHEN Q, CHEN J, QU CY. Research progress on the relationship between leptin, cholecystokinin and alcoholic fatty liver[J]. Chin Primary Health Care, 2008, 22(3): 92-93. DOI: 10.3969/j.issn.1001-568X.2008.03.044. 陈青, 陈吉, 曲春燕. 瘦素、胆囊收缩素与酒精性脂肪肝关系的研究进展[J]. 中国初级卫生保健, 2008, 22(3): 92-93. DOI: 10.3969/j.issn.1001-568X.2008.03.044.
[16]	SMITH SM, ENG RH, BUCCINI F. Use of D-lactic acid measurements in the diagnosis of bacterial infections[J]. J Infect Dis, 1986, 154(4): 658-664. DOI: 10.1093/infdis/154.4.658.
[17]	JIN X, LI YM, YU CH, et al. Changes of intestinal permeability during the formation of nonalcoholic steatohepatitis in rats[J]. Chin J Dig, 2006, 28(8): 547-548. DOI: 10.3760/j.issn:0254-1432.2006.08.013. 金希, 厉有名, 虞朝辉, 等. 大鼠非酒精性脂肪性肝炎形成过程中肠道通透性的变化[J]. 中华消化杂志, 2006, 28(8): 547-548. DOI: 10.3760/j.issn:0254-1432.2006.08.013.
[18]	SHEN Z, CEN L, CHEN X, et al. Increased risk of low bone mineral density in patients with non-alcoholic fatty liver disease: A cohort study[J]. Eur J Endocrinol, 2020, 182(2): 157-164. DOI: 10.1530/EJE-19-0699.
[19]	KEMPIŃSKI R, ŁUKAWSKA A, KRZYŻANOWSKI F, et al. Clinical outcomes of non-alcoholic fatty liver disease: Polish-case control study[J]. Adv Clin Exp Med, 2019, 28(12): 1615-1620. DOI: 10.17219/acem/106173.
[20]	WASHINGTON MC, COGGESHALL J, SAYEGH AI. Cholecystokinin-33 inhibits meal size and prolongs the subsequent intermeal interval[J]. Peptides, 2011, 32(5): 971-977. DOI: 10.1016/j.peptides.2011.02.007.
[21]	CHEN D. Clinical analysis of adiposis hepatica complicated with cholecystitis in aged people[J]. Inner Mongolia J Tradit Chin Med, 2008, 40(1): 50-51. DOI: 10.3969/j.issn.1004-0951.2008.01.019. 陈东. 老年人脂肪肝并发胆囊炎的临床观察[J]. 内蒙古医学杂志, 2008, 40(1): 50-51. DOI: 10.3969/j.issn.1004-0951.2008.01.019.
[22]	KEITH JN. Bedside nutrition assessment past, present, and future: A review of the Subjective Global Assessment[J]. Nutr Clin Pract, 2008, 23(4): 410-416. DOI: 10.1177/0884533608321215.
[23]	YE YH, WANG N, TAO W. Meta-analysis of the relationship between diamine oxidase changes and gastrointestinal dysfunction in critically ill patients[J/CD]. J Clin Med Literature (Electronic Edition), 2019, 6(4): 30-32, 34. DOI: 10.3877/j.issn.2095-8242.2019.04.017. 叶云虹, 王念, 陶武. 危重患者二胺氧化酶变化与胃肠功能障碍关系的meta分析[J/CD]. 临床医药文献电子杂志, 2019, 6(4): 30-32, 34. DOI: 10.3877/j.issn.2095-8242.2019.04.017.
[24]	CHENG J, LI FL, ZHANG B, et al. Effects of high-fat diet on intestinal flora and serum LPS level in NAFLD model rats[J]. Acta Univ Med Anhui, 2017, 52(9): 1341-1345. DOI: 10.19405/j.cnki.issn1000-1492.2017.09.019. 程靖, 李枫林, 张宝, 等. 高脂饮食对NAFLD模型大鼠肠道菌群及血清LPS水平的影响[J]. 安徽医科大学学报, 2017, 52(9): 1341-1345. DOI: 10.19405/j.cnki.issn1000-1492.2017.09.019.
[25]	CANI PD, AMAR J, IGLESIAS MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance[J]. Diabetes, 2007, 56(7): 1761-1772. DOI: 10.2337/db06-1491.
[26]	GUO RX, WEI XL, SHI XM, et al. Levels of serum sdiponectin, lipopolysaccharide and matrix metalloproteinase-2 in patients with liver cirrhosis and diagnostic value[J]. Chin J Mod Med, 2020, 30(12): 100-103. DOI: 10.3969/j.issn.1005-8982.2020.12.018. 郭瑞雪, 魏新亮, 史晓盟, 等. 肝硬化患者血清脂联素、脂多糖、基质金属蛋白酶-2水平及其诊断价值[J]. 中国现代医学杂志, 2020, 30(12): 100-103. DOI: 10.3969/j.issn.1005-8982.2020.12.018.
[27]	YANG YN, WAN WQ, ZHU DD, et al. Effect of lipopolysaccharide on expression of proteins associated with cell activation and apoptosis in human hepatic stellate cell line LX-2[J]. World Chin J Dig, 2013, 21(30): 3236-3240. https://www.cnki.com.cn/Article/CJFDTOTAL-XXHB201330015.htm 杨亚楠, 万维琴, 朱丹丹, 等. 脂多糖对人肝星状细胞株LX-2活化和凋亡相关蛋白表达的影响[J]. 世界华人消化杂志, 2013, 21(30): 3236-3240. https://www.cnki.com.cn/Article/CJFDTOTAL-XXHB201330015.htm
[28]	JIA JB, WU H, YANG DR, et al. Effect of endotoxin-stimulated Kupffer cells on procollagen gene expression in hepatic stellate cells[J]. Chin J Gastroenterol, 2011, 16(8): 459-463. DOI: 10.3969/j.issn.1008-7125.2011.08.003. 贾晋斌, 吴晗, 杨东仁, 等. 内毒素刺激Kupffer细胞对肝星状细胞前胶原基因表达的影响[J]. 胃肠病学, 2011, 16(8): 459-463. DOI: 10.3969/j.issn.1008-7125.2011.08.003.

Relative Articles

[1]	Huaqiang ZHANG, Lixin LIU, Xiaohong GUO. Association of nonalcoholic fatty liver disease with the risk of colorectal adenoma and colorectal cancer: A Meta-analysis[J]. Journal of Clinical Hepatology, 2021, 37(7): 1619-1625. doi: 10.3969/j.issn.1001-5256.2021.07.028
[2]	Qiaohong LIU, Yu ZHAO, Yiyang HU. Effect of diet on enterotype-related gut microbiota in nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(4): 939-942. doi: 10.3969/j.issn.1001-5256.2021.04.046
[3]	Juan PENG, Liangping LI. Mechanism of action of estrogen and its receptor in the development and progression of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(2): 467-470. doi: 10.3969/j.issn.1001-5256.2021.02.046
[4]	Jinhong TANG, Long WANG. Research advances in the association between nonalcoholic fatty liver disease and colorectal adenomatous polyps[J]. Journal of Clinical Hepatology, 2021, 37(11): 2672-2675. doi: 10.3969/j.issn.1001-5256.2021.11.040
[5]	Yalan LEI, Jian BI, Jingwei MAO. Impact of nonalcoholic fatty liver disease on intestinal immune cells[J]. Journal of Clinical Hepatology, 2021, 37(11): 2667-2671. doi: 10.3969/j.issn.1001-5256.2021.11.039
[6]	Shenglan ZENG, Rongzhen ZHANG, Na WANG, Tingshuai WANG, Liting TAN, Dewen MAO. Effect of diet-gut microbiota axis on nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(11): 2676-2679. doi: 10.3969/j.issn.1001-5256.2021.11.041
[7]	Chenlu ZHAO, Wenxia ZHAO. Influence of estrogen deficiency on metabolic associated fatty liver disease in postmenopausal women[J]. Journal of Clinical Hepatology, 2021, 37(7): 1708-1712. doi: 10.3969/j.issn.1001-5256.2021.07.049
[8]	Tian TIAN, Wenwei HU, Xue LI, Jie WU, Dan ZHANG, Changzheng LI. Association between thyroxine level and nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(10): 2357-2363. doi: 10.3969/j.issn.1001-5256.2021.10.020
[9]	Xiangqian HUANG, Xiaomeng YAN, Mingda ZHANG, Jing WU, Jianhong CHEN. Association between nonalcoholic fatty liver disease and colorectal neoplasms[J]. Journal of Clinical Hepatology, 2021, 37(12): 2947-2950. doi: 10.3969/j.issn.1001-5256.2021.12.045
[10]	SUN MengYuan, XIANG XiaoXing. Role of gut microbiota and bile acid pathway in nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(12): 2831-2834. doi: 10.3969/j.issn.1001-5256.2020.12.040
[11]	Li HongShan, Hu YiYang. Gut microecology: An important target of traditional Chinese medicine in the treatment of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(1): 14-18. doi: 10.3969/j.issn.1001-5256.2020.01.002
[12]	Hui DengCheng, Sun MingYu. Association between nonalcoholic fatty liver disease and gut microbiota based on the theory of gut-liver axis[J]. Journal of Clinical Hepatology, 2020, 36(7): 1627-1630. doi: 10.3969/j.issn.1001-5256.2020.07.039
[13]	Zhang Dan, Zhou Bo, Deng Yi, Wen Yu, Lu: JunYan, Wang JinXiang, Geng ZuoTao, Luo SuFeng, Ying YunYan, Wen DaiYan, Shi ChunJing, Pu GuangYu, Jiang Xin, Ma LanQing. Effect of fenofibrate on the diversity of intestinal flora in a mouse model of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(4): 829-834. doi: 10.3969/j.issn.1001-5256.2020.04.024
[14]	Chuan LiXue, Chang Jiang, Zhao JinHan, Li LuoHua, Yang XuYao, Yu Di. Association between nonalcoholic fatty liver disease and colorectal adenomatous polyps[J]. Journal of Clinical Hepatology, 2020, 36(6): 1299-1303. doi: 10.3969/j.issn.1001-5256.2020.06.022
[15]	Feng Gong, He Na, Mi Man, Li XuePing, Liu ManLing, Fan LiPing, Niu ChunYan. Risk factors for the coexistence of inflammatory bowel disease and nonalcoholic fatty liver disease: A Meta-analysis[J]. Journal of Clinical Hepatology, 2019, 35(4): 835-839. doi: 10.3969/j.issn.1001-5256.2019.04.025
[16]	Liu SiFu, Xie ZhengYuan. Association between nonalcoholic fatty liver disease and colorectal tumors[J]. Journal of Clinical Hepatology, 2019, 35(9): 2091-2094. doi: 10.3969/j.issn.1001-5256.2019.09.046
[17]	Zhang XiaXia, Xu HongTuan, Xu YouQing. The natural history and clinical features of nonalcoholic fatty liver disease-related cirrhosis[J]. Journal of Clinical Hepatology, 2018, 34(1): 24-26. doi: 10.3969/j.issn.1001-5256.2018.01.004
[18]	Liu JiaQi, Zhou ShaoMing. Research advances in intestinal flora in nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2017, 33(12): 2453-2456. doi: 10.3969/j.issn.1001-5256.2017.12.045
[19]	Lu Xu, Han Tao, Tian Yao, Lu BoWei, Zhang Qian. Research progress in roles of gut microbiota and bile acid metabolism in development and progression of NAFLD[J]. Journal of Clinical Hepatology, 2014, 30(11): 1225-1228. doi: 10.3969/j.issn.1001-5256.2014.11.034
[20]	Zhu Peng, Xu Zong, Wang YuMing. World Gastroenterology Organisation global guidelines：nonalcoholic fatty liver disease and nonalcoholic steatohepatitis[J]. Journal of Clinical Hepatology, 2014, 30(9): 842-845. doi: 10.3969/j.issn.1001-5256.2014.09.002

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Tables(2)

Get Citation

PDF

XML

Article Metrics

Article views (485) PDF downloads(30)

Expression levels of gastrointestinal hormones in the progression of liver fibrosis in patients with nonalcoholic fatty liver disease

DOI: 10.3969/j.issn.1001-5256.2021.10.021

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content